Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesDose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy
Cancer, 08/17/09
Shayne M et al. – No differences with regard to chemotherapy-related hematologic toxicities between older and younger breast cancer patients in this large prospective observational study was recorded; partly attributed to more frequent reductions in relative dose intensity (RDI) and less frequent utilization of anthracyclines among older patients.
Methods- An evaluation of patient and treatment characteristics that contributed to hematologic toxicity in older BCa pts
- Data collected on 1224 pts with stage I through III BCa, of whom 207 were ≥65 yrs
- Primary outcome measures: anemia, thrombocytopenia, severe neutropenia, febrile neutropenia, and both planned and actual RDI
- Comparisons between older and younger pts regarding hematologic toxicity and reductions in RDI based on univariate and multivariate logistic regression analyses
- Neutropenic complication rates were similar in older and younger pts
- No differences in rates of anemia or thrombocytopenia
- Approx. 34.0% of the older pts received RDI <85% vs 20.0% among younger pts
- Fewer older pts received anthracycline-based chemotherapy vs younger pts
- Fewer older pts received prophylactic white blood cell colony-stimulating factor vs younger pts
Related Articles
Effects of chronic hepatitis C infection on the treatment of breast cancer patients
Annals of Oncology, 11/06/09
Relevance Score: 89%
North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 88%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 88%
Lapatinib in metastatic breast cancer
Women's Health, 10/30/09
Relevance Score: 88%
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Relevance Score: 88%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Extracellular Signal–Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
Cancer Research, 12/20/09
Breast cancer with non-inflammatory skin involvement: Current data on an underreported entity and its problematic classification
The Breast, 12/19/09
Flat epithelial atypia is a common subtype of B3 breast lesions and associated with noninvasive cancer but not with invasive cancer in final excision histology
Human Pathology, 12/19/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
Haematologica, 12/18/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/18/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor